Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.

Abstract: A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ?ID?NO:?1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ?ID?NO:?2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.

Abstract: A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ?ID?NO:?1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ?ID?NO:?2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.

Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.

Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH (SEQ ID NO:1) as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.

Abstract: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.

Abstract: The present invention is related to newly identified compounds, polynucleotide sequences encoding the amino acid sequences of the compounds, as well as agonists, antagonists or inhibitors of the compounds for chemokine receptors, especially the CCR-5 receptor and their use in the field of diagnostics and therapeutics involving the chemokine receptors.

Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.

Abstract: The invention relates to tissue inhibitor of metalloproteinase-2 (TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.

Abstract: A serine protease inhibitor, characterized by having a domain with four cysteines, and a sequence of 0 to 20 amino acids is present between the first and second cysteines, or the serine protease inhibitor has a domain with six cysteines, and a sequence of 7 to 20 amino acids is present between the first and second cysteines.

Abstract: A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.

Abstract: The invention relates to serine protease inhibitors having the amino acid sequence in accordance with Seq. ID No. 1.

Abstract: A peptide referred to as cadherin-derived growth factor (CDGF) the sequence of which corresponds to a partial sequence of a pre-pro-cadherin, said pre-pro-cadherin comprising the domains signal sequence, pro sequence cadherin repeats, transmembrane region and intracellular domain, characterized in that the sequence of said peptide comprises the pro sequence, that at least one of the other domains of the pre-pro-cadherin is lacking, and that said peptide has cell-proliferative, cell-protective and/or cell-differential properties.

Abstract: The invention relates to TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.

Abstract: The present invention is related to newly identified compounds, polynucleotide sequences encoding the amino acid sequences of the compounds, as well as agonists, antagonists or inhibitors of the compounds for chemokine receptors, especially the CCR-5 receptor and their use in the field of diagnostics and therapeutics involving the chemokine receptors.